Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

AML
Biomarker-Driven Lung Cancer
Bladder Cancer
Breast Cancer
CAR T-Cell Therapy
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Genomic Testing
GI Cancers
Gynecologic Cancers
HCC
Hematology
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Thyroid Cancers
More >>

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

Targeted Therapies in Oncology
July 2

Clinical Articles

More Actionable Targets Improve Therapy in NSCLC
Updated KEYNOTE-048 Data Show PD-1 Inhibitor Improves OS in HNSCC
Barriers to Interpreting Results in Molecular Profiling Exist Among Oncologists
KEYNOTE-048 Leads to First-Line Advances in Monotherapy, Chemotherapy for Head and Neck Cancer
IDH Mutations Offer Hope as a Prognostic Indicator and Treatable Target in Gliomas
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.